JADE COMPARE Analysis: Defining the Depth and Rapidity of Response of Abrocitinib and Dupilumab in Patients With Moderate to Severe Atopic Dermatitis

AAAAI February 26 - March 1, 2021, AAD VMX April 23-25, 2021; Virtual
Study suggests that treatment with abrocitinib 200 mg QD results in a greater and more rapid response vs dupilumab, as assessed using stringent endpoints.
Format: Microsoft PowerPoint (.ppt)
File Size: 455 KB
Released: June 15, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Incyte Corporation

Related Content

Expert faculty Benjamin Ungar, MD, discusses current and future treatment options for patients with prurigo nodularis (PN) from Clinical Care Options (CCO).

Benjamin Ungar, MD Released: September 16, 2022

Expert commentary reviews key concepts in the diagnosis and treatment of chronic spontaneous urticaria from Clinical Care Options (CCO).

Jonathan A. Bernstein, MD Released: September 15, 2022

Expert slides on new and emerging therapies, reducing healthcare disparities, and transitions of care in the management of moderate to severe atopic dermatitis

Robert Sidbury, MD, MPH Benjamin Ungar, MD Released: September 9, 2022

From Clinical Care Options (CCO) and Dr. Robert Sidbury, expert commentary on new data in atopic dermatitis evaluation and management.

Robert Sidbury, MD, MPH Released: June 30, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings